Patient-related outcomes for metastatic prostate cancer

Affiliations

¹ Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: ebasch@med.unc.edu.

Comment

Ethan Basch. Lancet Oncol. 2015 May.

. 2015 May;16(5):477-8.

doi: 10.1016/S1470-2045(15)70171-3. Epub 2015 Apr 14.

¹ Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: ebasch@med.unc.edu.

No abstract available

Comment on

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B. Loriot Y, et al. Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25888263 Clinical Trial.